Muscarinic agonists for the treatment of cognition in schizophrenia (Q28301970)

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

Europe PubMed Central

title

Muscarinic agonists for the treatment of cognition in schizophrenia (English)

0 references

0 references

3

Carol Tamminga

0 references

author name string

Angela K Sellin

series ordinal

1

0 references

Mujeeb Shad

series ordinal

2

0 references

language of work or name

English

0 references

publication date

November 2008

0 references

published in

C N S Spectrums

0 references

volume

13

0 references

issue

11

0 references

page(s)

985-96

0 references

cites work

1 reference

https://api.crossref.org/works/10.1017/S1092852900014048

Cognitive neuroscience: forgetting of things past.

21 April 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Neuropsychological differentiation of late-onset schizophrenia and dementia of the Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Pharmacologic strategies for augmenting cognitive performance in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Muscarinic receptor ligands and their therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Muscarinic receptors as a target for drugs treating schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Cholinergic systems and schizophrenia: primary pathology or epiphenomena?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

AF150(S): a new functionally selective M1 agonist improves cognitive performance in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Facilitation of memory performance by a novel muscarinic agonist in young and old rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Muscarinic mechanisms of antipsychotic atypicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Pharmacology of N-desmethylclozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Effects of desmethylclozapine on Fos protein expression in the forebrain: in vivo biological activity of the clozapine metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Identification of separable cognitive factors in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Treatment of cognitive dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Central muscarinic acetylcholine receptor availability in patients treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Functional hypofrontality and working memory dysfunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Anterior cingulate cortex, error detection, and the online monitoring of performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

First- and second-generation antipsychotic medication and cognitive processing in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Assessing cognitive function in schizophrenics and patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Galantamine for the treatment of cognitive impairments in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Medicine. What are the right targets for psychopharmacology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Galantamine for treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Donepezil in schizophrenia--is it helpful? An experimental design case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

Alterations in hippocampal mossy fiber pathway in schizophrenia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Activation of muscarinic receptors inhibits apoptosis in PC12M1 cells

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Defining a cognitive function decrement in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Growth factor-like effects mediated by muscarinic receptors in PC12M1 cells

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Donepezil management of schizophrenia with associated dementia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021

Cognitive functions of cortical acetylcholine: toward a unifying hypothesis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900014048

7 January 2021